Increased polyp and adenoma detection rates are associated with use of full-spectrum endoscopy colonoscope.
Time to tumor growth proved to be the best metric for predicting overall survival in persons with metastatic colorectal cancer on bevacizumab.
Phase 3 trial evaluating Vectibix vs. Erbitux for the treatment of chemo-refractory metastatic colorectal cancer meets its primary endpoint for overall survival.
Having more comprehensive discussions about colorectal cancer screening with primary care providers (PCPs) is associated with increased odds of screening.
Adverse events associated with regorafenib are manageable with a proactive strategy that includes prophylactic treatment and education for the patient, caregiver, and healthcare provider, research presented at the ONS 38th Annual Congress has shown.
Combining cetuximab (Erbitux) with standard therapy improved the resectability of previously inoperable liver metastases of colorectal cancer.
Before Medicare halted coverage for screening CT colonography in March 2009, the technique was indeed being used appropriately, a study has found.
Although the absolute risk is low, use of anesthesia for colonoscopy is associated with a somewhat higher frequency of complications.
For elderly patients with metastatic colorectal cancer, certain geriatric scores were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan.
A new study adds support to current medical recommendations stating that screening colonoscopy substantially reduced the likelihood of advanced CRC in either the right or left side of the colon being diagnosed in an average-risk adult.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|